References
Bovili EG, Terrin ML, Stump DC, Berke AD, Frederick M, et al. Haemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Annals of Internal Medicine 115: 256–265, 1991
Califf RM, Topol EJ, George BS, Boswick JM, Abbottsmith C, et al. Haemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction. American Journal of Medicine 85: 353–359, 1988
Chaitman BR, Thompson B, Wittry MD, Stump D, Hamilton WP, et al. The use of tissue-type plasminogen activator for acute myocardial infarction in the elderly: results from the Thrombolysis in Myocardial Infarction Phase I open label studies and the Thrombolysis in Myocardial Infarction Phase II Pilot Study. Journal of the American College of Cardiology 14: 1159–65, 1989
Collins R, Julian D. British Heart Foundation surveys (1987 and 1989) of United Kingdom treatment policies for acute myocardial infarction. British Heart Journal 66: 250–255, 1991
Cragg DR, Friedman HZ, Bonema JD, Jaiyesimi IA, Ramos RG, et al. Outcome of patients with acute myocardial infarction who are ineligible for thrombolytic therapy. Annals of Internal Medicine 115: 173–177, 1991
Eigler N, Maurer G, Shah PK. Effect of early systemic thrombolytic therapy on left ventricular mural thrombus formation in acute anterior myocardial infarction. American Journal of Cardiology 54: 261–263, 1984
Ellis SG, O’Neill WW, Bates ER, Walton JA, Nabel EG, et al. Implications for patient triage from survival and left ventricular functional recovery analyses in 500 patients treated with coronary angioplasty for acute infarction. Journal of the American College of Cardiology 13: 1251–1259, 1989
Granger C, Kalbfleisch J, Califf R, Woodlief L, Karnash S, Topol E. The Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded coronary arteries (GUSTO) pilot study: Combined streptokinase and t-PA. Abstract. Circulation 84: II–573, 1991
Goldberg RJ, Gore JM, Gurwitz JH, Alpert JS, Brady P, et al. The impact of age on the incidence and prognosis of initial acute myocardial infarction: the Worchester Heart Attack Study. American Heart Journal 117: 543–549, 1989
Gore JM, Sloan M, Price TR, Randal AMY, Bovill E, et al. Intracerebral haemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction study: Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial. Circulation 83: 448–459, 1991
GISSI-2. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. GISSI-2: a factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12, 490 patients with acute myocardial infarction. Lancet 336: 65–71, 1990
GISSI. Gruppo Italiano per lo Studio della Streptochinasi nell’ Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1: 397–401, 1986
Holland KJ, O’Neill WW, Bates ER, Pitt B, Topol EJ. Emergency percutaneous transluminal coronary angioplasty during acute myocardial infarction for patients more than 70 years of age. American Journal of Cardiology 63: 399–403, 1989
The International Study Group. In-hospital mortality and clinical course of 20, 891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 336: 71–75, 1990
ISIS-2 Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17, 187 case of suspected acute myocardial infarction: ISIS-2. Lancet 2: 349–360, 1988
Konrad MS, Coffey CE, Coffey KS, McKinnis RA, Massey EW, Califf RM. Myocardial infarction and stroke. Neurology 34: 1403–1409, 1978
Kudenchuk PJ, Ho MT, Weaver WD, Litwin PE, Martin JS, et al. Accuracy of computer-interpreted electrocardiography in selecting patients for thrombolytic therapy. Journal of the American College of Cardiology 17: 1486–1491, 1991
Lee L, Bates ER, Pitt B, Walton, JA, Laufer N, et al. Percutaneous transluminal coronary angioplasty improves survival in acute myocardial infarction complicated by cardiogenic shock. Circulation 78: 1345–1351, 1988
Lew AS, Hod H, Cercek B, Shah Pk, Ganz W. Mortality and morbidity rates of patients older and younger than 75 years with acute myocardial infarction treated with intravenous streptokinase. American Journal Cardiology 59: 1–5, 1987
Muller DWM, Topol EJ. Selection of patients with acute myocardial infarction for thrombolytic therapy. Annals of Internal Medicine 113: 949–960, 1990
O’Connor CM, Califf RM, Massey EW, Mark DB, Kereiakes DJ, et al. Stroke and acute myocardial infarction in the thrombolytic era: Clinical correlates and long-term prognosis. Journal of the American College of Cardiology 16: 533–540, 1990
Peto R. Which patients to treat with fibrinolysis: overview of ISIS-3, EMERAS, et al. Presented at the American College of Cardiology 40th Annual Scientific Session, Atlanta, Georgia, March 5, 1991
Rao AK, Pratt C, Rerke A, Jaffe A, Ockene I, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial — Phase I: Haemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. Journal of the American College of Cardiology 11: 1–11, 1988
Report of the Working Group on Arteriosclerosis of the National Heart, Lung and Blood Institute. US. Department of Health and Human Services. Public Health Service Publication Number (NIH) 81-2034, p. 39, 1981
Thompson PL, Robinson JS. Stroke after acute myocardial infarction: Relation to infarct size. British Medical Journal 2: 457–459, 1978
TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of Thrombolysis in Myocardial Infarction (TIMI) Phase II trial. New England Journal of Medicine 320: 618–627, 1989
Topol EJ. Thrombolytic intervention. In Topol EJ (Ed.) Textbook of interventional cardiology, pp. 79–120, WB Saunders, Philadelphia, 1989
Weaver WD, Litwin PE, Martin JS, Kudenchuk PJ, Maynard C, et al. Effect of age on use of thrombolytic therapy and mortality in acute myocardial infarction. Journal of the American College of Cardiology 18: 657–662, 1991
Wilcox RG, Olsson CG, Skene AM, Von Der Lippe G, Jensen G, et al. for the ASSET Study Group. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 2: 525–530, 1988
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Williamson, B.D., Muller, D.W.M. & Topol, E.J. Should Older Patients with Acute Myocardial Infarction Receive Thrombolytic Therapy?. Drug & Aging 2, 461–468 (1992). https://doi.org/10.2165/00002512-199202060-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002512-199202060-00002